Chardan Healthcare Acquisition 2 Corp. was a blank check company, sponsored by an affiliate of Chardan Capital Markets LLC, incorporated for the purpose of effecting a merger, share exchange, asset acquisition, or similar business combination with one or more businesses. The company raised approximately $115 million in its initial public offering in October 2020, with a stated focus on identifying a target in the healthcare industry, including the biotechnology, medical technology, and healthcare services sectors. In September 2021, the company successfully completed its business combination with Renovacor, Inc., a preclinical-stage gene therapy company.

Founded in

United States